反式-叔丁基-3-羟基-4-(甲基氨基)吡咯烷-1-羧酸叔丁酯 | 203503-49-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 反式-叔丁基-3-羟基-4-(甲基氨基)吡咯烷-1-羧酸叔丁酯
• 英文名称: (3R,4R)-tert-butyl-3-hydroxy-4-(methylamino)pyrrolidine-1-carboxylate
• 英文别名: tert-butyl (3R,4R)-3-hydroxy-4-(methylamino)pyrrolidine-1-carboxylate
• CAS: 203503-49-5
• 化学式: C₁₀H₂₀N₂O₃
• mdl: MFCD10686936
• 分子量: 216.28
• InChiKey: IJLLHXGWHBTSPV-HTQZYQBOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  61.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  反式-叔丁基-3-羟基-4-(甲基氨基)吡咯烷-1-羧酸叔丁酯 在 二乙胺基三氟化硫 、 sodium cyanoborohydride 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 5.25h， 生成 trans-tert-butyl-3-(dimethylamino)-4-fluoropyrrolidine-1-carboxylate
  参考文献：
  名称：

  [EN] SPIROINDOLINONES AS DDR1 INHIBITORS
  [FR] SPIROINDOLINONES UTILISÉS EN TANT QU'INHIBITEURS DE DDR1

  摘要：

  本发明涉及式(I)的化合物或其药用盐，以及其制备方法、包含它们的药物组合物，以及它们作为药物的用途。

  公开号：

  WO2017137334A1

文献信息

• Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040220191A1

  公开（公告）日：2004-11-04

  The invention relates to substituted N-aryl heterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I 1 in which the radicals have the stated meanings, the N-oxides and the physiologically tolerated salts thereof and process for the preparation thereof are described. The compounds are suitable for example as anorectic agents.

  本发明涉及替代的N-芳基杂环化合物及其生理上可耐受的盐和生理上功能衍生物。本发明描述了式I1的化合物，其中基团具有所述含义，其N-氧化物和生理上可耐受的盐以及其制备方法。这些化合物例如适用于作为减肥剂。
• Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments
  申请人：Schwink Lothar

  公开号：US20070207991A1

  公开（公告）日：2007-09-06

  The invention relates to substituted N-aryl heterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I in which the radicals have the stated meanings the N-oxides and the physiologically tolerated salts thereof and process for the preparation thereof are described. The compounds are suitable for example as anorectic agents.

  该发明涉及取代的N-芳基杂环化合物及其生理耐受盐和生理功能衍生物。描述了公式I中化合物，其中基团具有所述的含义，以及其N-氧化物和生理耐受盐和其制备方法。这些化合物例如适用于作为抑制食欲的药物。
• Amide Derivative and Medicine
  申请人：Asaki Tetsuo

  公开号：US20080293940A1

  公开（公告）日：2008-11-27

  The present invention is directed to an amide derivative having excellent BCR-ABL tyrosine kinase inhibitory activity, or a salt thereof. The present invention provides an amide derivative represented by the following general formula (1): [Chemical 23] (wherein R 1 represents —CH 2 —R 11 , etc.; R 2 represents alkyl, halogen, haloalkyl, etc.; R 3 represents hydrogen, etc.; Het1 represents a group of the formula [6] as above, etc.; and Het2 represents pyrimidinyl, etc.), or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.

  本发明涉及具有优异的BCR-ABL酪氨酸激酶抑制活性的酰胺衍生物或其盐。本发明提供了由下述通式（1）表示的酰胺衍生物：[化学式23]（其中，R1代表—CH2—R11等；R2代表烷基、卤素、卤代烷基等；R3代表氢等；Het1代表如上所述的[6]式基团等；Het2代表嘧啶基等），或其药学上可接受的盐，并且提供了包含其作为活性成分的制药组合物。本发明的化合物在作为BCR-ABL酪氨酸激酶抑制剂方面是有用的。
• 1-cyano-pyrrolidine compounds as USP30 inhibitors
  申请人：MISSION THERAPEUTICS LIMITED

  公开号：US10343992B2

  公开（公告）日：2019-07-09

  The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, R9, R10, R12, Z, Y and m are as defined herein.

  本发明涉及新型化合物和去泛素化酶（DUB）抑制剂的制造方法。特别是，本发明涉及泛素 C 端水解酶 30（USP30）的抑制。本发明还涉及 DUB 抑制剂在治疗线粒体功能障碍和癌症方面的用途。本发明的化合物包括具有式(II)的化合物或其药学上可接受的盐，其中R1、R2、R3、R4、R5、R8、R9、R10、R12、Z、Y和m如本文所定义。
• Spiroindolinones as DDR1 inhibitors
  申请人：Hoffmann-La Roche Inc.

  公开号：US10618897B2

  公开（公告）日：2020-04-14

  The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.

  本发明涉及式（I）化合物： 或其药学上可接受的盐类，以及它们的制造工艺、包含它们的药物组合物和它们作为药物的用途。